Dangerous genital infection linked to common diabetes meds, FDA warns
A type 2 diabetes drug taken by nearly 2 million patients last year has led to “rare but serious genital infections”, and at least one death. The FDA is now requiring additional warning labels on the packaging of all sodium-glucose contransporter-2 (SGLT2) inhibitors.
When bacteria enters the body of patients taking these drugs through a cut or scrape, it can cause necrotizing fasciitis of the perineum, also called Fournier's gangrene. Over a 5 year testing period the FDA found 12 cases of Fournier's gangrene in patients prescribed SGLT2, a drug that was original approved in 2013. These findings while alarming, don’t even take into account any unreported cases. The number of patients suffering from Fournier's gangrene while taking other Type 2 diabetes prescription medications was much, much lower at just 6 instances in 30 years.
The potentially harmful Type 2 diabetes medications are: Invokana, Invokamet, Invokamet XR, Farxiga, Xigduo XR, Qtern, Jardiance, Glyxambi, Synjardy, Synjardy XR, Steglatro, Segluromet and Steglujan. If you’re experiencing “tenderness, redness or swelling of the genitals, or the area from the genitals back to the rectum, and have a fever above 100.4 F or a general feeling of being unwell,” the FDA advises that you seek medical attention immediately. Any patients that are found to be suffering from Fournier's gangrene will be treated with “a broad spectrum of antibiotics” and surgery may be necessary.
To read the full report from CBS News, follow this link: https://cbsn.ws/2CfamIy